- BioMarin (BMRN +8.3%) has put together a strong session after starting the day only slightly higher.
- Available now are the briefing docs for next week's Vimizim Ad Com.
- FDA staff characterizes the benefit conferred on Morquio A patients as "modest."
- Full documents
FDA says BioMarin drug results in "modest" improvements
Recommended For You
More Trending News
About BMRN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
BMRN | - | - |
BioMarin Pharmaceutical Inc. |